uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now
Show others and affiliations
2011 (English)In: Drug resistance updates, ISSN 1368-7646, E-ISSN 1532-2084, Vol. 14, no 2, 118-124 p.Article, review/survey (Refereed) Published
Abstract [en]

Two commercial databases (Pharmaprojects and Adis Insight R&D) were queried for antibacterial agents in clinical development. Particular attention was given to antibacterial agents for systemic administration. For each agent, reviewers were requested to indicate whether its spectrum of activity covered a set of selected multidrug-resistant bacteria, and whether it had a new mechanism of action or a new target. In addition, PubMed was searched for antibacterial agents in development that appeared in review articles. Out of 90 agents that were considered to fulfil the inclusion criteria for the analysis, 66 were new active substances. Fifteen of these could be systemically administered and were assessed as acting via a new or possibly new mechanism of action or on a new or possibly new target. Out of these, 12 agents were assessed as having documented in vitro activity against antibiotic-resistant Gram-positive bacteria and only four had documented in vitro activity against antibiotic-resistant Gram-negative bacteria. Of these four, two acted on new or possibly new targets and, crucially, none acted via new mechanisms of action. There is an urgent need to address the lack of effective treatments to meet the increasing public health burden caused by multidrug-resistant bacteria, in particular against Gram-negative bacteria.

Place, publisher, year, edition, pages
2011. Vol. 14, no 2, 118-124 p.
Keyword [en]
Antibiotics, Antimicrobial resistance, Antibiotic resistance, Antibacterial drug development, Novel antimicrobials, Multidrug resistant bacteria, Gap-analysis, EMA, ECDC, ReAct
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-155453DOI: 10.1016/j.drup.2011.02.003ISI: 000291375900008OAI: oai:DiVA.org:uu-155453DiVA: diva2:426113
Available from: 2011-06-22 Created: 2011-06-22 Last updated: 2017-12-11Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text
By organisation
Department of Medical SciencesInfectious Diseases
In the same journal
Drug resistance updates
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 397 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf